Boyang Bian

502 total citations
19 papers, 372 citations indexed

About

Boyang Bian is a scholar working on Economics and Econometrics, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Boyang Bian has authored 19 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 5 papers in Physiology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Boyang Bian's work include Pharmaceutical Economics and Policy (5 papers), Asthma and respiratory diseases (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Boyang Bian is often cited by papers focused on Pharmaceutical Economics and Policy (5 papers), Asthma and respiratory diseases (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Boyang Bian collaborates with scholars based in United States and China. Boyang Bian's co-authors include Jeff J. Guo, Christina M.L. Kelton, Dennis W. Raisch, John Doyle, Y. Lis, Patricia R. Wigle, Pamela C. Heaton, Katherine Tsai, Kaan Tunceli and Phil Schwab and has published in prestigious journals such as Neurology, Obesity and Value in Health.

In The Last Decade

Boyang Bian

16 papers receiving 355 citations

Peers

Countries citing papers authored by Boyang Bian

Since Specialization

Citations

This map shows the geographic impact of Boyang Bian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boyang Bian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boyang Bian more than expected).

Fields of papers citing papers by Boyang Bian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boyang Bian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boyang Bian. The network helps show where Boyang Bian may publish in the future.

Co-authorship network of co-authors of Boyang Bian

This figure shows the co-authorship network connecting the top 25 collaborators of Boyang Bian. A scholar is included among the top collaborators of Boyang Bian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boyang Bian. Boyang Bian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Lentinan Alleviated PM2.5 Exposure-Induced Epithelial–Mesenchymal Transition in Pulmonary Epithelial Cells by Inhibiting the GARP/TGF-β/Smad Pathway 2025 ·Toxics ·Zhi Wang, Shiqing Xu, Boyang Bian, Ziang Hu, Feifei Wu, Siqi Zhao, Xiaohui Wang, Li Wang, (unknown)	1
2	Exposure to Polyethylene Terephthalate Microplastic Induces Mouse Liver Fibrosis Through Oxidative Stress and p38 MAPK/p65 NF‐κB Signaling Pathway 2025 ·Journal of Applied Toxicology ·Ru‐Rong Ji, (unknown), Boyang Bian, Yafeng Zhang, Feifei Wang, (unknown)	0
3	Long-Term Clinical Outcomes Following the WATCHMAN Device Use in Medicare Beneficiaries 2024 ·Circulation Cardiovascular Quality and Outcomes ·Emily P. Zeitler, Boyang Bian, Robert I. Griffiths, Dominic J. Allocco, (unknown), Kristine Roy, David J. Cohen, Matthew R. Reynolds	0
4	Polyethylene Terephthalate Microplastic Exposure Induced Reproductive Toxicity Through Oxidative Stress and p38 Signaling Pathway Activation in Male Mice 2024 ·Toxics ·Tianyang Li, Boyang Bian, Ru‐Rong Ji, Xiuwen Zhu, (unknown), (unknown), Zhigang Li, Feifei Wang, (unknown)	8
5	Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005) 2024 ·Neurology ·(unknown), (unknown), Chu‐Yueh Guo, Sylvia Klineova, Jong‐Mi Lee, Rebecca Romero, (unknown), (unknown), Jason P. Mendoza, (unknown), Boyang Bian, (unknown), (unknown)	0
6	Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study 2016 ·Journal of Managed Care & Specialty Pharmacy ·Shengsheng Yu, Phil Schwab, Boyang Bian, Larry Radican, Kaan Tunceli	18
7	Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010 2015 ·Obesity ·(unknown), Christina M.L. Kelton, Jeff J. Guo, Boyang Bian, Pamela C. Heaton	73
8	Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008 2014 ·Applied Health Economics and Health Policy ·Christina M.L. Kelton, (unknown), Jeff J. Guo, Yan Yu, (unknown), Boyang Bian, Pamela C. Heaton	8
9	Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma 2013 ·Therapeutic Advances in Drug Safety ·Ying Xia, Christina M.L. Kelton, (unknown), Jeff J. Guo, Boyang Bian, Patricia R. Wigle	20
10	PRS30 Inhaled Corticosteroid and Long-Acting Beta-Agonist Medication Compliance in Patients with Moderate and Severe Asthma 2012 ·Value in Health ·Jing Guo, (unknown), Katherine Tsai, Beilei Cai, Boyang Bian, Patricia R. Wigle	2
11	Long-Term Medicaid Excess Payments from Alleged Price Manipulation of Generic Lorazepam 2012 ·Journal of Managed Care Pharmacy ·Boyang Bian, (unknown), Christina M.L. Kelton, Jeff J. Guo, (unknown)	1
12	Utilization, Spending, and Price Trends for Benzodiazepines in the US Medicaid Program: 1991-2009 2012 ·Annals of Pharmacotherapy ·(unknown), Boyang Bian, Christina M.L. Kelton, (unknown), Jeff J. Guo	23
13	Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: A retrospective cohort study 2011 ·Annals of Allergy Asthma & Immunology ·Jeff J. Guo, Katherine Tsai, Christina M.L. Kelton, Boyang Bian, Patricia R. Wigle	25
14	Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey 2011 ·Value in Health ·(unknown), Boyang Bian, Christina M.L. Kelton, (unknown), Jeff J. Guo	3
15	Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma 2010 ·Current Drug Safety ·Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle, Jeff J. Guo	8
16	PRS1 RISK OF SERIOUS ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING-BETA-AGONISTS AMONG MEDICAID PATIENTS WITH ASTHMA:A RETROSPECTIVE COHORT STUDY 2010 ·Value in Health ·(unknown), Katherine Tsai, (unknown), Boyang Bian, Patricia R. Wigle	1
17	A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group 2010 ·Value in Health ·Jeff J. Guo, (unknown), John Doyle, Boyang Bian, Y. Lis, Dennis W. Raisch	150
18	ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008 2010 ·Journal of Managed Care Pharmacy ·Boyang Bian, Christina M.L. Kelton, Jeff J. Guo, Patricia R. Wigle	29
19	PRS5 EVALUATING SAFETY OUTCOMES OF LONG-ACTING BETA AGONISTS (LABAS) IN PATIENTS WITH ASTHMA 2010 ·Value in Health ·Boyang Bian, (unknown), (unknown), Patricia R. Wigle	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact